[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
December 12, 2001

Cardiovascular Events and COX-2 Inhibitors

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor

JAMA. 2001;286(22):2808-2813. doi:10.1001/jama.286.22.2808

To The Editor: Dr Mukherjee and colleagues1 present the CV event data from CLASS study (Figure 2) in an inconsistent fashion. Summary data from the US Food and Drug Administration hearings on the safety of celecoxib during the CLASS trial2 are the primary source for this figure. Review of these data reveals that MI and stroke rates are presented as crude event rates while deaths are displayed as annualized incidence rates. Moreover, deaths include all cause deaths, rather than CV deaths. The correct crude event rates for CV deaths in CLASS are 0.57% (aspirin users) and 0.16% (non-aspirin users).2

First Page Preview View Large
First page PDF preview
First page PDF preview
×